Condition (MeSH)
Growth Hormone-Secreting Pituitary Adenoma
ClinicalTrials.gov lists 12 trials for Growth Hormone-Secreting Pituitary Adenoma or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
12 of the 12 trials are tagged with Growth Hormone-Secreting Pituitary Adenoma itself; the rest are tagged with a narrower condition beneath it.
When did Growth Hormone-Secreting Pituitary Adenoma trials start? (9)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 3 |
| 2023 | 1 |
| 2019 | 1 |
| 2018 | 1 |
| 2014 | 1 |
| 2009 | 1 |
| 2005 | 1 |
| 1998 | 1 |
No forecast is made for this condition: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 12 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Growth Hormone-Secreting Pituitary Adenoma trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
| Phase 3 | 2 |
| Not applicable | 4 |
| Observational | 3 |
How many Growth Hormone-Secreting Pituitary Adenoma trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 3 |
| Completed | 3 |
| Withdrawn | 2 |
| Unknown status | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Growth Hormone-Secreting Pituitary Adenoma trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Başakşehir Çam & Sakura City Hospital | 1 |
| Novartis Pharmaceuticals | 1 |
Which drugs are being tested for Growth Hormone-Secreting Pituitary Adenoma? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| antineoplaston A10 | 1 |
Interventions as named in the registry (8)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Ketogenic diet | 2 |
| GIP-A | 1 |
| SOC: Temozolomide | 1 |
| Lanreotide 60Mg Solution for Injection | 1 |
| Observational Study | 1 |
Showing 5 of 8 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Growth Hormone-Secreting Pituitary Adenoma? (32)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| The clinical aspects of pituitary tumour genetics. | Endocrine | 2021 | Yes |
| Significant Benefits of AIP Testing and Clinical Screening in Familial Isolated and Young-onset Pituitary Tumors. | The Journal of clinical endocrinology and metabolism | 2020 | Yes |
| Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN). | BMC endocrine disorders | 2020 | Yes |
| Postoperative Diabetes Insipidus and Hyponatremia in Children after Transsphenoidal Surgery for Adrenocorticotropin Hormone and Growth Hormone Secreting Adenomas. | The Journal of pediatrics | 2018 | Yes |
| Classification of Patients With GH Disorders May Vary According to the IGF-I Assay. | The Journal of clinical endocrinology and metabolism | 2017 | Yes |
Showing 5 of 32 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.